Comparative Risk of New-Onset Seizure Among Smoking Cessation Pharmacotherapies
Abstract number :
2.128
Submission category :
17. Public Health
Year :
2025
Submission ID :
199
Source :
www.aesnet.org
Presentation date :
12/7/2025 12:00:00 AM
Published date :
Authors :
Presenting Author: Cameron Gordon, MD – University of Mississippi Medical Center
Shade Smith, BS – University of Mississippi Medical Center
Jonathan Hontzas, AGACNP-BC, DNP – University of Mississippi Medical Center
Seth Lirette, PhD – University of Mississippi Medical Center
Alexander Kile, BS – UC San Diego Health
Nader Pahlevan, MD – University of Colorado
Nazm Rahat, BS – University of Mississippi Medical Center
Olga Selioutski, DO – Stony Brook University
Rationale: Despite recent declining prevalence, cigarette smoking remains the leading cause of preventable death in the United States.1 Pharmacologic interventions for smoking cessation are effective and recommended by the United States Preventive Services Task Force (USPSTF) for non-pregnant adult tobacco users.2 However, certain approved pharmacotherapies have been implicated in lowering seizure threshold.3 We aimed to investigate the association between smoking cessation therapy (SCT) use and self-reported seizures.
Methods: This is a retrospective IRB-approved project. We identified 5,174 records of seizure-free adults who were later started on SCT by the ACT Center for Tobacco Treatment, Education, and Research between 2007 and 2019. Subsequent incidence of seizure reporting was analyzed by Cox survival analysis. Hazard ratio was calculated for comparison of seizure incidence based on the type of SCT. A p-value of < 0.05 was considered significant.
Public Health